Skip to content
  • About us
    • Mission
    • Strategy
    • Our story
    • Our team
  • Inobrodib
    • Science
    • Publications
  • Clinical trials
    • Indications under investigation
    • Current clinical trials
  • News
    • Press releases
  • Contact us
  • About us
    • Mission
    • Strategy
    • Our story
    • Our team
  • Inobrodib
    • Science
    • Publications
  • Clinical trials
    • Indications under investigation
    • Current clinical trials
  • News
    • Press releases
  • Contact us
Twitter

Category: Team

Applications

Inobrodib is currently being evaluated for safety and effectiveness in multiple specific settings

FDC40D06-9F76-4E8A-AF33-68251D6B17C1

Haematological Malignancies

Blood cancers including multiple myeloma, acute myeloid leukaemia, myelodysplastic syndrome and lymphomas

5ED9A5DB-1645-4854-AFCE-FF80DBBE114F
70F65CDB-84D7-4DBF-B9A3-94D23EB86997

Solid Tumours

Metastatic castrate-resistant prostate cancer (mCRPC) and other targeted tumours.

8B1E0328-3F62-4701-A135-6606C5F74CC5

About CellCentric

CellCentric is a clinical stage biotech company focused on the development of a first of its kind, p300/CBP inhibitor to treat specific cancer types.

Quick Links

  • About us
  • Inobrodib
  • Clinical trials
  • Publications
  • Our story
Menu
  • About us
  • Inobrodib
  • Clinical trials
  • Publications
  • Our story
  • Our team
  • Press releases
  • News
  • Contact
Menu
  • Our team
  • Press releases
  • News
  • Contact

Follow us

Follow us and stay up to date with our latest news, events and scientific posters.

Twitter Linkedin-in

© CellCentric Limited 2023 | Company #4948632

Designed and built by OSM Group

  • About us
    • Mission
    • Strategy
    • Our story
    • Our team
  • Inobrodib
    • Science
    • Publications
  • Clinical trials
    • Indications under investigation
    • Current clinical trials
  • News
    • Press releases
  • Contact us
Follow us on Twitter